Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial

• Shernan G. Holtan,

  Affiliation Mayo Clinic Rochester, Rochester, Minnesota, United States of America

  ⨯
• Preston D. Steen,

  Affiliation Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States of America

  ⨯
• Nathan R. Foster,

  Affiliation Mayo Clinic Rochester, Rochester, Minnesota, United States of America

  ⨯
• Charles Erlichman,

  Affiliation Mayo Clinic Rochester, Rochester, Minnesota, United States of America

  ⨯
• Fabiola Medeiros,

  Affiliation Mayo Clinic Rochester, Rochester, Minnesota, United States of America

  ⨯
• Matthew M. Ames,

  Affiliation Mayo Clinic Rochester, Rochester, Minnesota, United States of America

  ⨯
• Stephanie L. Safgren,

  Affiliation Mayo Clinic Rochester, Rochester, Minnesota, United States of America

  ⨯
• David L. Graham,

  Affiliation Carle Cancer Center CCOP, Urbana, Illinois, United States of America

  ⨯
• Robert J. Behrens,

  Affiliation Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States of America

  ⨯
• Matthew P. Goetz

  * E-mail: goetz.matthew@mayo.edu

  Affiliation Mayo Clinic Rochester, Rochester, Minnesota, United States of America

  ⨯